A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide).
When topical controlled delivery of ophthalmic drugs is realised via erodible inserts, drug bioavailability is maximised, if release is controlled exclusively by insert erosion, since parallel mechanisms which increase the release rate, also increases the dose fraction cleared from the precorneal area by tear fluid draining. The respective contributions of diffusion and erosion to the release mechanism of different drugs, namely, prednisolone (PDS), oxytetracycline hydrochloride (OTH) and gentamicin sulfate (GTS), from erodible ocular inserts based on poly(ethylene oxide) (PEO) of molecular weight 400 or 900kDa was determined by an in vitro technique adequate to predict the release mechanism in vivo. PDS and OTH were released with erosion-controlled kinetics. With therapeutic doses of these drugs in the inserts (0.3mg, 1.5%), the possibility of a purely erosive mechanism was shown to rely upon drug-PEO molecular interactions, which limit drug diffusion in the swollen matrix. This was the case with OTH, for which strong interactions with PEO were measured, whereas some contribution from the parallel diffusive mechanism was evidenced for PDS, which showed weaker interactions with polymer. Such a contribution disappeared when the PDS concentration in the insert was increased to 6%, which suggested that the erosive mechanism is favoured by a drug concentration in the hydrated insert substantially higher than solubility. On the other hand, the release of about 50% GTS dose was controlled by diffusion, due to the high water solubility of this drug, accompanied by weak drug-PEO interactions. In this case the residence time of drug in the precorneal area is expected to be significantly shorter than that of the PEO carrier.
Di Colo
G
G
Department of Bioorganic Chemistry and Biopharmaceutics, University of Pisa, Pisa, Italy. giadic@farm.unipi.it
Zambito
Y
Y
D001566:Benzocaine / Q000737:chemistry; D055598:Chemical Phenomena; D002626:Chemistry, Pharmaceutical; D002627:Chemistry, Physical; D003692:Delayed-Action Preparations / Q000737:chemistry; D005079:Excipients / Q000737:chemistry*; D005839:Gentamicins / Q000737:chemistry; D007700:Kinetics; D008970:Molecular Weight; D015242:Ofloxacin / Q000737:chemistry; D009883:Ophthalmic Solutions / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D011239:Prednisolone / Q000737:chemistry
D003692:Delayed-Action Preparations; D005079:Excipients; D005839:Gentamicins; D009883:Ophthalmic Solutions; D011092:Polyethylene Glycols; D011239:Prednisolone; D015242:Ofloxacin; D001566:Benzocaine